Ireland’s Mr IPO and his plans to make more companies public
Cathal Friel shows no sign of slowing down after a busy week which saw him sell his remaining stake in Hvivo
Amryt Pharma
Poolbeg Pharma expands treatment into new markets
Company signs strategic collaboration agreement with a Nasdaq listed biopharma company
Upcoming Irish and overseas elections may affect M&A activity this year, William Fry warns
Falling interest rates may offer some support but acquirers are wary of policy changes here and abroad
Cathal Friel-chaired green metals company hires broker for London IPO
Flotation of Irish-run company could take place as soon as March
Life sciences a rare bright spot in muted Irish M&A activity last year - EY
Deal volumes in the Republic were down in 2023 but in value terms were up nearly 600 per cent year on year, according to EY analysis
Irish deal-making ‘muted’ amid global slump
Value of M&A transactions fell 58% to €5.2bn in first half, says William Fry
Amryt pays dividends for big investors
US funds make $79m profit on investment in Irish rare disease drug developer, and could yet make another $62.5m
Amryt strikes gold with rare-disease breakthrough
Irish pharma company secures a 100%-plus premium for shareholders in deal to sell the business to bigger Italian rival
Irish rare disease drugmaker Amryt Pharma to be acquired for up to €1.4bn
Eight-year old Amryt got EU approval last year for first treatment for rare genetic condition known as butterfly skin disease that primarily affects children
Amryt announces plan to delist from AIM in London
Drug firm says says delisting would enhance liquidity of trading
Irish pharma group Amryt reports 15% revenue growth for third quarter
Rare disease specialist says performance was ‘strong’ in ‘extremely busy’ period
Amryt Pharma granted priority review of ‘butterfly skin’ treatment
US Food and Drug Administration’s priority review can expedite review process to six months
Amryt progresses with bid to win US approval for ‘butterfly skin’ treatment
Rolling submission began last summer
Butterfly skin drug group Amryt announces €33m fundraise
Placing of shares comes ahead of submission to regulators for approval of drug for rare condition
Biopharma group Amryt reports 19% jump in revenue in third quarter
Results are a record for Dublin-based company, which has recently listed on Nasdaq
Amryt signs agreement to distribute Lojuxta
Swixx BioPharma will sell cholesterol drug across central and eastern Europe
Amryt shares surge on success in drug trial for ‘butterfly skin’
Irish specialist in rare diseases says successful drug could tap $1bn market
EY Entrepreneur of the Year international finalists focusing on growth
Sectors include health and safety, pharma, crop protection and refrigeration
Investor exercises rights to 4m Amryt warrants
Warrants were issued in September as part of the company’s acquisition of Aegerion
Irish pharma company Amryt almost doubles CEO pay to $1.6m
Chief executive Joe Wiley also received more than 6m share options in company
Amryt Pharma files registration statement for impending Nasdaq listing
Company recently signed distribution agreement with Swixx BioPharma
Biopharma group Amryt reports 30% jump in revenue
Rare disease specialist says integration with newly acquired Aegerion completed ahead of time
Amryt Pharma recorded 13.1% rise in revenue last year
Company said the impact of Covid-19 on its business has been minimised so far
Amryt says integration of acquired company Aegerion ‘progressing well’
Dublin-based biopharma company has cash position of $60.9m
‘Serious gender imbalance’ remains at top of Irish business, report finds
New targets set for inclusion of women on leadership teams and in private companies
Dublin pharma company Amryt grows sales almost 20%
Firm acquired US-based Aegerion Pharmaceuticals earlier this year
Venn signs deal with Open Orphan to focus on rare diseases
Company has issued €1.1m in loan notes to fund specialisation in orphan diseases
Iseq slumps to lowest since Brexit referendum as key vote delayed
Markets also rattled by growing unrest in France and fresh China-US trade concerns
Government provides €75m in funding for ‘disruptive’ projects
Company that received the most funding was biopharmaceutical group Amryt Pharma
Carrick Therapeutics head Sullivan named best emerging entrepreneur
Elaine Sullivan leads cancer research firm to an EY Entrepreneur of the Year Award
Irish shares advance for first time in five sessions
European markets buoyed by speculation that US could resume trade talks with China
Sales of Amryt Pharma cholesterol drug up 14.6%
Amyrt’s EB development asset progressing through phase three clinical trial
Amryt skin therapy trial gets green light in US
Approval for treatment for rare genetic condition paves way for clinical trials in US
Amryt Pharma wins key US drug designation
FDA move means Irish company could receive voucher ultimately worth up to €300m
Amryt Pharma heart drug wins approval from NHS England
Drug treats rare condition which can lead to early blocking of arteries and heart attacks
Dublin entrepreneur targeting treatments for rare diseases
EY Entrepreneur of the Year finalist Dr Joe Wiley of Amryt Pharma
Amryt signs new deal to expand Lojuxta licence
Firms estimates new deal will increase number of patients for treatment by 25%
EY Entrepreneur of the Year: 24 companies shortlisted for award
Finalists employ more than 2,700 people and generate annual revenues of €150m
Amryt Pharma signs distribution agreement in middle east
Company has further expanded its market coverage for Lojuxta
Amryt Pharma appoints new head of regulatory affairs
Derval O’Carroll has more than 25 years experience in pharmaceutical industry
Amryt Pharma signs deal for drug distribution in Switzerland
Lojuxta deal is ‘key step’ in growing company’s business for drug in EMEA region
Amryt Pharma to raise €15m to treat rare skin disorder
Placing is conditional on shareholder approval at a general meeting on October 9th
Sales jump at rare disease drug group Amryt Pharma
Company starts phase III trial for ‘butterfly skin’ disease
Here's what’s happening in the business week ahead
For Your Diary: Exchequer returns; Dalata results; Dell results; ECB rate decision
Amryt Pharma enrols first patient on EB drug trial
Irish company says therapy for skin blistering condition is its prime pipeline candidate
All the major business events happening this week
For Your Diary: Dell, Ladbrokes Coral and Datalex report;Theresa May triggers Brext
Declines in miners, energy producers drag equities lower
Investors worry central banks less willing to use monetary policy to stimulate growth
Fastnet shareholders back Amryt Pharma reverse takeover
All-cash deal for Fastnet also involved raising £10m (€12.5m) for future acquisitions
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices